173 related articles for article (PubMed ID: 7693979)
1. Intracavernous vasoactive pharmacotherapy: the impact of a new self-injection device.
Montorsi F; Guazzoni G; Bergamaschi F; Orlandini A; Da Pozzo L; Barbieri L; Rigatti P
J Urol; 1993 Dec; 150(6):1829-32. PubMed ID: 7693979
[TBL] [Abstract][Full Text] [Related]
2. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
[TBL] [Abstract][Full Text] [Related]
3. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence.
Montorsi F; Guazzoni G; Bergamaschi F; Zucconi M; Rigatti P; Pizzini G; Miani A; Pozza G
Acta Diabetol; 1994 Apr; 31(1):1-5. PubMed ID: 8043890
[TBL] [Abstract][Full Text] [Related]
4. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
von Heyden B; Donatucci CF; Kaula N; Lue TF
J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
[TBL] [Abstract][Full Text] [Related]
5. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
Vardi Y; Lidgi S; Moskovitz B; Levin RD
Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
[TBL] [Abstract][Full Text] [Related]
6. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
Asuar Aydillo S
Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
[No Abstract] [Full Text] [Related]
7. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
Lee LM; Stevenson RW; Szasz G
J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
[TBL] [Abstract][Full Text] [Related]
8. Intracavernous drug-induced erections in the management of male erectile dysfunction: experience with 100 patients.
Sidi AA; Cameron JS; Duffy LM; Lange PH
J Urol; 1986 Apr; 135(4):704-6. PubMed ID: 2421014
[TBL] [Abstract][Full Text] [Related]
9. Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction.
Montorsi F; Guazzoni G; Bergamaschi F; Ferini-Strambi L; Barbieri L; Rigatti P
J Urol; 1993 May; 149(5 Pt 2):1291-5. PubMed ID: 7683061
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
Meinhardt W; Lycklama à Nijeholt AA; Kropman RF; Vermeij P; Zwartendijk J
Eur Urol; 1994; 26(4):319-21. PubMed ID: 7713130
[TBL] [Abstract][Full Text] [Related]
13. Experience with triple-drug therapy in a pharmacological erection program.
Govier FE; McClure RD; Weissman RM; Gibbons RP; Pritchett TR; Kramer-Levien D
J Urol; 1993 Dec; 150(6):1822-4. PubMed ID: 8230514
[TBL] [Abstract][Full Text] [Related]
14. Classification of sexual dysfunction for management of intracavernous medication-induced erections.
Fein RL
J Urol; 1990 Feb; 143(2):298-301. PubMed ID: 1688954
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and therapeutic technology assessment. Vasoactive intracavernous pharmacotherapy for impotence: papaverine and phentolamine.
JAMA; 1990 Aug; 264(6):752-4. PubMed ID: 2374280
[No Abstract] [Full Text] [Related]
16. Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction.
Ghanem H; Sherif T; Adbel-Gawad T; Asaad T
Int J Impot Res; 1998 Dec; 10(4):211-4. PubMed ID: 9884916
[TBL] [Abstract][Full Text] [Related]
17. The application of intracavernous injection of vasoactive medications for erection in men with spinal cord injury.
Bodner DR; Lindan R; Leffler E; Kursh ED; Resnick MI
J Urol; 1987 Aug; 138(2):310-1. PubMed ID: 3599245
[TBL] [Abstract][Full Text] [Related]
18. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
Valdevenito R; Melman A
Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
[TBL] [Abstract][Full Text] [Related]
19. [3 years' experience with intracavernous auto-injection therapy].
Weiske WH
Urologe A; 1989 Sep; 28(5):253-6. PubMed ID: 2815435
[TBL] [Abstract][Full Text] [Related]
20. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
Engel JD; McVary KT
Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
